Case Report: Generating Hypotheses by Discovering Implicit Associations in the Literature: A Case Report of a Search for New Potential Therapeutic Uses for Thalidomide
暂无分享,去创建一个
Marc Weeber | Alan R. Aronson | Henny Klein | Lolkje T. W. de Jong-van den Berg | Rein Vos | Grietje Molema | A. Aronson | M. Weeber | G. Molema | L. J. D. Berg | R. Vos | H. Klein | L. T. Berg
[1] J. Wingard,et al. Thalidomide in Children Undergoing Bone Marrow Transplantation: Series at a Single Institution and Review of the Literature , 1999, Pediatrics.
[2] J. Thèze,et al. The cytokine network and immune functions , 1999 .
[3] A. Saoudi,et al. Is pathogenic humoral autoimmunity a Th1 response? , 2000, Immunology today.
[4] Marc Weeber,et al. Using concepts in literature-based discovery: Simulating Swanson's Raynaud-fish oil and migraine-magnesium discoveries , 2001, J. Assoc. Inf. Sci. Technol..
[5] N R Smalheiser,et al. Using ARROWSMITH: a computer-assisted approach to formulating and assessing scientific hypotheses. , 1998, Computer methods and programs in biomedicine.
[6] D. Adams,et al. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. , 1999, Journal of immunology.
[7] R. Pezzilli,et al. Behavior of serum interleukin 12 in human acute pancreatitis. , 1999, Pancreas.
[8] J. Devière,et al. Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice , 1998, Gut.
[9] Neil R. Smalheiser,et al. Artificial Intelligence An interactive system for finding complementary literatures : a stimulus to scientific discovery , 1995 .
[10] D F Roychowdhury,et al. Aspirin and the risk of colorectal cancer in women. , 1996, The New England journal of medicine.
[11] N. Raje,et al. Thalidomide--a revival story. , 1999, The New England journal of medicine.
[12] R. Powell,et al. New roles for thalidomide , 1996, BMJ.
[13] R. Pirskanen,et al. Decreased mRNA expression of TNF‐α and IL‐10 in non‐stimulated peripheral blood mononuclear cells in myasthenia gravis , 2000, European journal of neurology.
[14] D. Swanson. Migraine and Magnesium: Eleven Neglected Connections , 2015, Perspectives in biology and medicine.
[15] J. McHutchison,et al. A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[16] Marc Weeber,et al. Text-based discovery in biomedicine: the architecture of the DAD-system , 2000, AMIA.
[17] G. Trinchieri,et al. Inhibition of IL-12 production by thalidomide. , 1997, Journal of immunology.
[18] H. Yagita,et al. Suppressive effect on Theiler's murine encephalomyelitis virus-induced demyelinating disease by the administration of anti-IL-12 antibody. , 1998, Journal of immunology.
[19] V. Rivera,et al. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS , 2000, Neurology.
[20] C. McKay,et al. Increased monocyte cytokine production in association with systemic complications in acute pancreatitis , 1996, The British journal of surgery.
[21] J A Quiroga,et al. Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. , 1998, The Journal of infectious diseases.
[22] B. Sands,et al. New life in a sleeper: thalidomide and Crohn's disease. , 1999, Gastroenterology.
[23] F Charatan. First pill for male impotence approved in US , 1998, BMJ.
[24] D. Swanson. Fish Oil, Raynaud's Syndrome, and Undiscovered Public Knowledge , 2015, Perspectives in biology and medicine.
[25] P. Haslett,et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.
[26] G. Lauer,et al. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. , 1997, Journal of hepatology.
[27] A. Pestronk,et al. The effect of thalidomide on experimental autoimmune myasthenia gravis. , 1989, Journal of autoimmunity.
[28] Ken B. Waites,et al. Helicobacter pylori-Induced Mucosal Inflammation Is Th1 Mediated and Exacerbated in IL-4, But Not IFN-γ, Gene-Deficient Mice1 , 2000, The Journal of Immunology.
[29] T G Blanchard,et al. Review article: Immunological determinants that may affect the Helicobacter pylori cancer risk. , 1998, Alimentary pharmacology & therapeutics.
[30] G Muller,et al. Thalidomide as an emerging immunotherapeutic agent. , 1999, Immunology today.
[31] Yoshiyuki Ueno,et al. Profiles of cytokines produced by CD4-positive T lymphocytes stimulated by anti-CD3 antibody in patients with chronic hepatitis C , 1998, Journal of Gastroenterology.
[32] M. Pirisi,et al. Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN-alpha in chronic hepatitis C. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[33] P Nieuwenhuis,et al. Single expression of CD45RC and RT6 in correlation with T-helper 1 and T-helper 2 cytokine patterns in the rat. , 2000, Cellular immunology.
[34] S. Joshi‐Barve,et al. Cytokine Production by CAPAN-1 and CAPAN-2 Cell Lines , 2000, Digestive Diseases and Sciences.
[35] R A Miller,et al. Making the conceptual connections: the Unified Medical Language System (UMLS) after a decade of research and development. , 1998, Journal of the American Medical Informatics Association : JAMIA.
[36] P. Marcellin,et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. , 1999, Journal of hepatology.
[37] R. Callard,et al. The cytokine factsbook , 1994 .
[38] R. Pirskanen,et al. Tumor necrosis factor-α, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis , 1996, Journal of Neuroimmunology.
[39] Stewart,et al. Iron absorption in patients with Zollinger–Ellison syndrome treated with long‐term gastric acid antisecretory therapy , 1998, Alimentary pharmacology & therapeutics.
[40] Rein Vos,et al. Drugs Looking for Diseases , 1991, Developments in Cardiovascular Medicine.
[41] Don R. Swanson,et al. Complementary structures in disjoint science literatures , 1991, SIGIR '91.
[42] S. Ashley,et al. Interleukin 10 reduces the severity of acute pancreatitis in rats. , 1997, Gastroenterology.
[43] P S Sastry,et al. Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis. , 1999, Medical hypotheses.
[44] G. Bishop,et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1‐associated cytokines , 1996, Hepatology.
[45] Susan Mayor. Trial supports earlier screening for Down's syndrome , 1998 .
[46] R A Lawrence,et al. The effects of early pacifier use on breastfeeding duration. , 1999, Pediatrics.
[47] C M Lockwood,et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen‐ and antigen‐stimulated human peripheral blood mononuclear cell cultures , 1995, Clinical and experimental immunology.
[48] Alan R. Aronson,et al. Effective mapping of biomedical text to the UMLS Metathesaurus: the MetaMap program , 2001, AMIA.
[49] A. Fleischer,et al. Thalidomide: current and potential clinical applications. , 2000, The American journal of medicine.
[50] V H Price,et al. Treatment of hair loss. , 1999, The New England journal of medicine.
[51] Š. Mesaroš,et al. Interleukin-12 and tumor necrosis factor-α levels in cerebrospinal fluid of multiple sclerosis patients , 1997, Journal of the Neurological Sciences.
[52] J. Raufman,et al. Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C , 2001, American Journal of Gastroenterology.